Centre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway; Centre for Immune Regulation and Department of Biosciences, University of Oslo, Oslo, Norway; KG Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Centre for Immune Regulation and Department of Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway.
Gastroenterology. 2019 Apr;156(5):1428-1439.e10. doi: 10.1053/j.gastro.2018.12.013. Epub 2018 Dec 26.
BACKGROUND & AIMS: Development of celiac disease is believed to involve the transglutaminase-dependent response of CD4 T cells toward deamidated gluten peptides in the intestinal mucosa of individuals with specific HLA-DQ haplotypes. We investigated the antigen presentation process during this mucosal immune response.
We generated monoclonal antibodies (mAbs) specific for the peptide-MHC (pMHC) complex of HLA-DQ2.5 and the immunodominant gluten epitope DQ2.5-glia-α1a using phage display. We used these mAbs to assess gluten peptide presentation and phenotypes of presenting cells by flow cytometry and enzyme-linked immune absorbent spot (ELISPOT) in freshly prepared single-cell suspensions from intestinal biopsies from 40 patients with celiac disease (35 untreated and 5 on a gluten-free diet) as well as 18 subjects with confirmed noninflamed gut mucosa (controls, 12 presumed healthy, 5 undergoing pancreatoduodenectomy, and 1 with potential celiac disease).
Using the mAbs, we detected MHC complexes on cells from intestinal biopsies from patients with celiac disease who consume gluten, but not from patients on gluten-free diets. We found B cells and plasma cells to be the most abundant cells that present DQ2.5-glia-α1a in the inflamed mucosa. We identified a subset of plasma cells that expresses B-cell receptors (BCR) specific for gluten peptides or the autoantigen transglutaminase 2 (TG2). Expression of MHC class II (MHCII) was not restricted to these specific plasma cells in patients with celiac disease but was observed in an average 30% of gut plasma cells from patients and controls.
A population of plasma cells from intestinal biopsies of patients with celiac disease express MHCII; this is the most abundant cell type presenting the immunodominant gluten peptide DQ2.5-glia-α1a in the tissues from these patients. These results indicate that plasma cells in the gut can function as antigen-presenting cells and might promote and maintain intestinal inflammation in patients with celiac disease or other inflammatory disorders.
人们认为,乳糜泻的发病机制涉及到具有特定 HLA-DQ 单倍型的个体的肠道黏膜中,CD4 T 细胞对转谷氨酰胺酶依赖性的脱酰胺麸质肽的反应。我们研究了在黏膜免疫反应期间的抗原呈递过程。
我们利用噬菌体展示技术,生成了针对 HLA-DQ2.5 肽-MHC(pMHC)复合物和免疫优势麸质表位 DQ2.5-glia-α1a 的单克隆抗体(mAb)。我们使用这些 mAb 通过流式细胞术和酶联免疫吸附斑点(ELISPOT)评估新鲜制备的来自 40 例乳糜泻患者(35 例未经治疗,5 例接受无麸质饮食)和 18 例经证实无炎症性肠黏膜的个体(对照组,12 例假定健康,5 例行胰十二指肠切除术,1 例有潜在乳糜泻)的肠活检的单个细胞悬液中,麸质肽的呈递和呈递细胞的表型。
使用 mAb,我们在摄入麸质的乳糜泻患者的活检肠道细胞中检测到 MHC 复合物,但在接受无麸质饮食的患者中没有检测到。我们发现 B 细胞和浆细胞是在炎症黏膜中呈递 DQ2.5-glia-α1a 的最丰富的细胞。我们鉴定出浆细胞的一个亚群表达针对麸质肽或自身抗原转谷氨酰胺酶 2(TG2)的 B 细胞受体(BCR)。在乳糜泻患者中,MHC II 的表达不仅限于这些特定的浆细胞,在患者和对照者的肠道浆细胞中也观察到平均 30%的表达。
乳糜泻患者的肠活检中的浆细胞群体表达 MHC II;这是在这些患者的组织中呈递免疫优势麸质肽 DQ2.5-glia-α1a 的最丰富的细胞类型。这些结果表明,肠道中的浆细胞可以作为抗原呈递细胞,并可能促进和维持乳糜泻患者或其他炎症性疾病患者的肠道炎症。